Will This Analyst Upgrade Help Immunogen (IMGN) Stock Today?

NEW YORK (TheStreet) -- UBS upgraded Immunogen  (IMGN) to "neutral" from "sell" and set a $13 price target. The firm noted a bullish outlook on Kadcyla and said royalty revenue is providing lower-risk valuation support. 

The stock closed at $12.13 on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

IMGN Chart

IMGN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

7 Stocks Under $10 Making Big Up Moves

Strong On High Relative Volume: Immunogen (IMGN)